VASOPRESSIN
Generic: VASOPRESSIN
Fresenius Kabi USAManufacturer
INTRAVENOUSRoute
VASOPRESSINActive Substance
2023-05-26Original Approval
VASOPRESSIN is FDA application ANDA213206, sponsored by FRESENIUS KABI USA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-08-06
Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx onlyCGMP Deviations
Class II2024-05-13
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous ISubpotent product in addition to having out-of-specification results for impurities.
Class II2026-08-06
Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container, Rx onlyCGMP Deviations
Top Reported Reactions
1
DRUG INEFFECTIVE
1,331 reports
2
OFF LABEL USE
536 reports
3
HYPOTENSION
500 reports
4
CARDIOGENIC SHOCK
417 reports
5
MULTIPLE ORGAN DYSFUNCTION SYNDROME
408 reports
6
SEPSIS
402 reports
7
CONDITION AGGRAVATED
388 reports
8
TOXICITY TO VARIOUS AGENTS
337 reports
9
ACUTE KIDNEY INJURY
331 reports
10
STRESS
310 reports